Disclosure of secondary findings in exome sequencing of 2480 Japanese cancer patients

[1]  T. Sugino,et al.  Japanese version of The Cancer Genome Atlas, JCGA, established using fresh frozen tumors obtained from 5143 cancer patients , 2019, Cancer science.

[2]  Lorenzo L. Pesce,et al.  Pathogenic and Uncertain Genetic Variants Have Clinical Cardiac Correlates in Diverse Biobank Participants , 2019, bioRxiv.

[3]  P. Butow,et al.  Challenges and strategies proposed by genetic health professionals to assist with family communication , 2019, European Journal of Human Genetics.

[4]  T. Aiba.  Recent understanding of clinical sequencing and gene-based risk stratification in inherited primary arrhythmia syndrome. , 2019, Journal of cardiology.

[5]  N. Spinner,et al.  Secondary findings from clinical genomic sequencing: prevalence, patient perspectives, family history assessment, and health-care costs from a multisite study , 2018, Genetics in Medicine.

[6]  Y. Kamatani,et al.  Germline pathogenic variants of 11 breast cancer genes in 7,051 Japanese patients and 11,241 controls , 2018, Nature Communications.

[7]  S. Richard,et al.  Guidelines for reporting secondary findings of genome sequencing in cancer genes: the SFMPP recommendations , 2018, European Journal of Human Genetics.

[8]  K. Brothers,et al.  Tensions in ethics and policy created by National Precision Medicine Programs , 2018, Human Genomics.

[9]  K. Kinoshita,et al.  Evaluation of reported pathogenic variants and their frequencies in a Japanese population based on a whole-genome reference panel of 2049 individuals , 2018, Journal of Human Genetics.

[10]  A. Hozawa,et al.  Population-based biobank participants’ preferences for receiving genetic test results , 2017, Journal of Human Genetics.

[11]  Matthew S. Lebo,et al.  A Model for Genome-First Care: Returning Secondary Genomic Findings to Participants and Their Healthcare Providers in a Large Research Cohort , 2017, bioRxiv.

[12]  Y. Bang,et al.  Findings of a 1303 Korean whole-exome sequencing study , 2017, Experimental &Molecular Medicine.

[13]  K. Offit,et al.  Interest and Attitudes of Patients With Advanced Cancer With Regard to Secondary Germline Findings From Tumor Genomic Profiling. , 2017, Journal of oncology practice.

[14]  Marylyn D. Ritchie,et al.  Distribution and clinical impact of functional variants in 50,726 whole-exome sequences from the DiscovEHR study , 2016, Science.

[15]  K. Yamaguchi,et al.  Integrated next-generation sequencing analysis of whole exome and 409 cancer-related genes. , 2016, Biomedical research.

[16]  K. Yamaguchi,et al.  Optimizing an ion semiconductor sequencing data analysis method to identify somatic mutations in the genomes of cancer cells in clinical tissue samples. , 2016, Biomedical research.

[17]  W. Chung,et al.  Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics , 2016, Genetics in Medicine.

[18]  Joshua L. Deignan,et al.  A survey of current practices for genomic sequencing test interpretation and reporting processes in US laboratories , 2016, Genetics in Medicine.

[19]  M. Dwyer,et al.  Genetic/Familial High-Risk Assessment: Colorectal Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. , 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

[20]  Y. Miki,et al.  Prevalence and differentiation of hereditary breast and ovarian cancers in Japan , 2015, Breast Cancer.

[21]  Sarah M. Hartz,et al.  Identification of Medically Actionable Secondary Findings in the 1000 Genomes , 2015, PloS one.

[22]  G. Petersen,et al.  Preferences regarding Return of Genomic Results to Relatives of Research Participants, Including after Participant Death: Empirical Results from a Cancer Biobank , 2015, Journal of Law, Medicine & Ethics.

[23]  Bartha Maria Knoppers,et al.  Return of genetic testing results in the era of whole-genome sequencing , 2015, Nature Reviews Genetics.

[24]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[25]  Jennifer B. McCormick,et al.  Patients' views on incidental findings from clinical exome sequencing , 2015, Applied & translational genomics.

[26]  D. Valle,et al.  Assessment of incidental findings in 232 whole exome sequences from the Baylor-Hopkins Center for Mendelian Genomics , 2014, Genetics in Medicine.

[27]  T. Nakajima,et al.  Implementation of individualized medicine for cancer patients by multiomics-based analyses—the Project HOPE—. , 2014, Biomedical research.

[28]  Deanna M. Church,et al.  ClinVar: public archive of relationships among sequence variation and human phenotype , 2013, Nucleic Acids Res..

[29]  E. Palmaer,et al.  Patient decisions for disclosure of secondary findings among the first 200 individuals undergoing clinical diagnostic exome sequencing , 2013, Genetics in Medicine.

[30]  B. Knoppers,et al.  Recommendations for returning genomic incidental findings? We need to talk! , 2013, Genetics in Medicine.

[31]  Marc S. Williams,et al.  ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing , 2013, Genetics in Medicine.

[32]  Larry N. Singh,et al.  Secondary variants in individuals undergoing exome sequencing: screening of 572 individuals identifies high-penetrance mutations in cancer-susceptibility genes. , 2012, American journal of human genetics.

[33]  Pablo Cingolani,et al.  © 2012 Landes Bioscience. Do not distribute. , 2022 .

[34]  M. Isobe,et al.  Prevalence and distribution of sarcomeric gene mutations in Japanese patients with familial hypertrophic cardiomyopathy. , 2012, Circulation journal : official journal of the Japanese Circulation Society.

[35]  Matthew Mort,et al.  The Human Gene Mutation Database: providing a comprehensive central mutation database for molecular diagnostics and personalised genomics , 2009, Human Genomics.

[36]  T. Iwama,et al.  Mechanism of carcinogenesis in familial tumors , 2004, International Journal of Clinical Oncology.

[37]  N. Gruis,et al.  Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16‐Leiden) , 2000, International journal of cancer.

[38]  P. Sham,et al.  Actionable secondary findings from whole-genome sequencing of 954 East Asians , 2017, Human Genetics.

[39]  JCSJointWorkingGroup.  Guidelines for Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy (JCS 2012)　- Digest Version . , 2016, Circulation journal : official journal of the Japanese Circulation Society.